Sonidegib
- Generic Name
- Sonidegib
- Brand Names
- Odomzo
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26F3N3O3
- CAS Number
- 956697-53-3
- Unique Ingredient Identifier
- 0RLU3VTK5M
- Background
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
- Indication
用于治疗那些在手术后或放射治疗后出现病情复发，或是不适合采用手术或放射治疗的局部晚期基底细胞癌（BCC）患者。BCC是常见皮肤癌，占所有非黑色素瘤病例的80%。
- Associated Conditions
- Refractory, locally advanced Basal cell carcinoma
Sonidegib in Adult Patients with Locally Advanced Basal Cell Carcinoma (laBCC) in China
- Conditions
- Carcinoma, Basal Cell (BCC)
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 160
- Registration Number
- NCT06880848
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 12
- Registration Number
- NCT05669339
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
- Conditions
- Basal Cell CarcinomaLocally Advanced Basal Cell CarcinomaBasal Cell Nevus SyndromeMetastatic Basal Cell CarcinomaGorlin SyndromeCarcinoma, Basal CellCarcinomaBasal Cell TumorSkin CancerNeoplasm of Skin
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT05463757
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
🇳🇱Maastricht University Medical Center +, Maastricht, Limburg, Netherlands
🇳🇱Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands
Tailored Sonidegib Schedule After Complete Response in BCC
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 21
- Registration Number
- NCT04806646
- Locations
- 🇮🇹
Asst Degli Spedali Civili Di Brescia, Brescia, Italy
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
- Conditions
- Medulloblastoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-08-26
- Target Recruit Count
- 20
- Registration Number
- NCT04402073
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇦🇺Austin Health - Austin hospital, Melbourne, Australia
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 323
- Registration Number
- NCT04066504
- Locations
- 🇮🇹
ASST Spedali Civili di Brescia, Brescia, Italy
🇩🇪Universitaets-Hautklinik Kiel, Kiel, Germany
🇩🇪Klinikum rechts der Isar, München, Germany
Sonidegib and Pembrolizumab in Treating Patients with Advanced Solid Tumors
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage III Gastric Cancer AJCC V8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Clinical Stage IV Gastric Cancer AJCC V8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8Locally Advanced Gastric AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaLocally Advanced Urothelial CarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT04007744
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
- Conditions
- Basal Cell CarcinomaBasal Cell Carcinoma of Skin, Site UnspecifiedInvasive CarcinomaSkin Cancer
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT03534947
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
- Conditions
- Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic GangliogliomaAnaplastic MeningiomaAnaplastic OligodendrogliomaPleomorphic Xanthoastrocytoma, AnaplasticAtypical Teratoid/Rhabdoid TumorBrain CancerBrain TumorCentral Nervous System Neoplasms
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03434262
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
- Conditions
- Carcinoma, Basal CellRecurrent Skin CancerBasal Cell Nevus SyndromeSkin Neoplasms
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Anne Chang
- Target Recruit Count
- 10
- Registration Number
- NCT02303041
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.